ZLABZai Lab Limited
Price
-23%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growth steady, the market undecided.
We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Zai Lab Limited (ZLAB) reported revenue of $106M in Q2 2026 (quarter ended Jun 30, 2026), down 3.3% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $51M. For the full year FY2025, revenue was $460M (+15% year on year) and net income −$176M. Its largest product in Q2 2026 was Zejula at $32M, 30% of the disclosed total, ahead of Vyvgart Vyvgart Hytrulo at 23%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Zai Lab Announces Second Quarter 2026.Earnings release · press release
- May 21, 2026On May 18, 2026, the Board of Directors of Zai Lab Limited (the “Company”) determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of employment with the Company will be May 22, 2026.Director or officer change · Form 8-K
- May 7, 2026Zai Lab Announces First Quarter 2026.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $105.8MThe company’s own SEC segment disclosure.
- Zejula$32.1M30%
- Vyvgart Vyvgart Hytrulo$23.9M23%
- Nuzyra$17.1M16%
- Optune$12.2M12%
- Qinlock$9.6M9%
- XACDURO$8.0M8%
- Other (3)$3.0M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.